CRD vs. Met in Patients With Obese PCOS Infertility
Polycystic Ovary Syndrome
About this trial
This is an interventional treatment trial for Polycystic Ovary Syndrome
Eligibility Criteria
Inclusion Criteria: a diagnosis of polycystic ovary syndrome (PCOS) based on the Rotterdam diagnostic criteria; age 20-35 years old; a body-mass index over 23; have requirements for fertility. Exclusion Criteria: acute or chronic viral hepatitis; serious liver dysfunction or chronic kidney disease; serious cardiovascular or cerebrovascular disease; patients with a history of acute/chronic infection, severe cardiovascular and cerebrovascular diseases, and malignant tumors; have drugs for PCOS such as glucocorticoids and anti-androgen drugs (spironolactone, cyproterone acetate, flutamide, etc.) within 3 months; congenital or secondary uterine abnormalities; use of medications that affect weight or energy balance such as Metformin within 3 months; undergoing weight loss treatment (weight change greater than 5% in the past 3 months) or have a history of gastrointestinal surgery; tubal obstruction; the total number of motile sperm of male partner is less than 10 million; any other situations that might affect the trial.
Sites / Locations
- Shanghai First Maternity and Infant HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Active Comparator
CRD group
Control group
Patients in the calorie-restricted diet (CRD) group will have strict calorie-restriction diets for 8 weeks and then weight stability for 4 weeks.
Patients in the control group will receive regular diets and metformin 1500 mg daily for 12 weeks. Participants allocated to the control group are followed by the conventional approach (usual care) based on regular visits respecting the usual schedule dictated by the rules of general practice.